# BE Study of Naftifine HCL

> **NCT02633813** · PHASE3 · COMPLETED · sponsor: **Genzum Life Sciences** · enrollment: 693 (actual)

## Conditions studied

- Tinea Pedis

## Interventions

- **DRUG:** Naftifine hydrochloride 2%
- **DRUG:** Placebo
- **DRUG:** Naftin® 2% (Naftifine hydrochloride 2%)

## Key facts

- **NCT ID:** NCT02633813
- **Lead sponsor:** Genzum Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2015-11
- **Final completion:** 2015-12
- **Target enrollment:** 693 (ACTUAL)
- **Last updated:** 2017-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02633813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02633813, "BE Study of Naftifine HCL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02633813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*